7 research outputs found

    Sensitivity analysis for combined HRs evaluating bFGF expression on OS.

    No full text
    <p>Sensitivity analysis for combined HRs evaluating bFGF expression on OS.</p

    Main characteristics of 22 eligible studies in the meta-analysis.

    No full text
    <p>IHC, immunohistochemistry; ELISA, enzyme linked immunosorbent assay; AC, adenocarcinoma; SCC, squamous cell carcinoma; Non-SCC, not squamous cell carcinoma; HR, hazard ration; ED, extensive-stage disease; LD, limited-disease stage; NA, not applicable; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.</p

    Forest plots of OS assessing bFGF expression in retrospective studies and prospective studies.

    No full text
    <p>Forest plots of OS assessing bFGF expression in retrospective studies and prospective studies.</p

    Forest plots of OS assessing bFGF expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

    No full text
    <p>Forest plots of OS assessing bFGF expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).</p

    Results of quality assessments according to ELCWP criteria.

    No full text
    <p>Score distributions are expressed by the mean values. IHC, immunohistochemistry; ELISA, enzyme linked immunosorbent assay; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; Significant, significant prognostic factor for survival (P<0.05); Non-significant, not significant prognostic factor for survival (P>0.05).</p

    Forest plots of OS associated with bFGF expression in lung cancer.

    No full text
    <p>Forest plots of OS associated with bFGF expression in lung cancer.</p

    Redox-Responsive Polymer–Drug Conjugates Based on Doxorubicin and Chitosan Oligosaccharide‑<i>g</i>‑stearic Acid for Cancer Therapy

    No full text
    Here, a biodegradable polymer–drug conjugate of doxorubicin (DOX) conjugated with a stearic acid-grafted chitosan oligosaccharide (CSO-SA) was synthesized via disulfide linkers. The obtained polymer–drug conjugate DOX-SS-CSO-SA could self-assemble into nanosized micelles in aqueous medium with a low critical micelle concentration. The size of the micelles was 62.8 nm with a narrow size distribution. In reducing environments, the DOX-SS-CSO-SA could rapidly disassemble result from the cleavage of the disulfide linkers and release the DOX. DOX-SS-CSO-SA had high efficiency for cellular uptake and rapidly released DOX in reductive intracellular environments. <i>In vitro</i> antitumor activity tests showed that the DOX-SS-CSO-SA had higher cytotoxicity against DOX-resistant cells than free DOX, with reversal ability up to 34.8-fold. DOX-SS-CSO-SA altered the drug distribution <i>in vivo</i>, which showed selectively accumulation in tumor and reduced nonspecific accumulation in hearts. <i>In vivo</i> antitumor studies demonstrated that DOX-SS-CSO-SA showed efficient suppression on tumor growth and relieved the DOX-induced cardiac injury. Therefore, DOX-SS-CSO-SA is a potential drug delivery system for safe and effective cancer therapy
    corecore